Warnings & Recalls for Intermezzo
Contraindications
The only known contraindication with this drug is hypersensitivity to zolpidem tartrate or any other component of the drug.
Precautions
Patients with these following preexisting conditions or patients currently on
Intermezzo | Zolpidem Tartrate must exercise caution whenever these warnings have arisen. These include:
- Abrupt withdrawal or rapid dose decrease
- Patients who concurrently drink alcohol with this drug
- Patients who concurrently use other sedatives or hypnotics
- Patients with depression
- Patients with diseases that affect metabolism or hemodynamic response
- Patients must be careful while driving vehicles or operating machinery after resuming activities
- Elderly or debilitated patients
- Patients with hepatic impairments
- Patients with myasthenia gravis
- Patients with renal impairments
- Patients with respiratory impairments
- Patients who have exhibited activities while asleep
- Patients with sleep apnea
- Patients with underlying comorbid physical or psychiatric disorders
Pregnancy Warning
Intermezzo | Zolpidem Tartrate has a pregnancy category rating of “C” by the FDA, implying that it should be discontinued after knowledge of conception by the expectant mother.
Intermezzo Treatment and Use
Intermezzo | Zolpidem Tartrate is a prescription medication approved by the FDA on November 23rd of 2011 indicated for patients who’ve got problems with waking during sleep and who’ve got difficulty falling back to sleep. The correct term for this condition is “early wakening” and is a form of insomnia that disables a person’s sleep patterns thereby affecting day-to-day activities and alertness.
The specific indications for this drug are for:
- Insomnia which is characterized by difficulty returning to sleep after middle-of-the-night awakening
- Short term treatment for insomnia
- Long term treatment for insomnia
- Insomnia resulting from selective serotonin reuptake inhibitors
Intermezzo | Zolpidem Tartrate comes as sublingual tablets meant to be taken orally. Zolpidem Tartrate is also known as Ambien CR, which was first approved in the US in 1992 for the short term treatment for insomnia as well as certain brain disorders.
How This Drug Works
Intermezzo | Zolpidem Tartrate is a hypnotic agent that’s unrelated to benzodiazepines or barbiturates. This drug binds the benzodiazepine (BZ) receptor subunit of a complex known as the GABA-A receptor complex that’s thought to be the source that’s responsible for sedative, anticonvulsant, anxiolytic and myorelaxant properties. The preferential binding of Zolpidem to the BZ receptor may explain Intermezzo | Zolpidem Tartrate’s relaxing attributes, enabling a patient to get better sleep.
Dosage Information
The safety and the efficacy of administering Intermezzo | Zolpidem Tartrate to pediatric patients has not been established as of yet. The following is the adult dosage for this drug and is meant to convey a variance between adult male patients and female patients. The difference between the doses for men and women is understood to be because of the slower metabolic clearance of this drug observed in female patients.
- The recommended and maximum dose for female patients is 1.75mg, taken once at night
- The recommended and maximum dose for male patients is 3.5mg, taken once at night